News Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2 Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.
News Lilly's tirzepatide juggernaut is still gathering momentum Lilly shrugs off concerns about the effect of US drug pricing policies on its diabetes and weight loss drugs as revenues leap 39% to $24.4bn.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.